Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00958776
Other study ID # BCX1812-301
Secondary ID
Status Terminated
Phase Phase 3
First received August 12, 2009
Last updated January 28, 2015
Start date November 2009
Est. completion date October 2013

Study information

Verified date January 2015
Source BioCryst Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

A Phase 3, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of peramivir administered intravenously in addition to standard of care compared to standard of care alone in adults and adolescents who are hospitalized due to serious influenza.


Recruitment information / eligibility

Status Terminated
Enrollment 405
Est. completion date October 2013
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender Both
Age group 12 Years and older
Eligibility Inclusion Criteria:

- Age =12 years of age, male or female.

- Able to provide informed consent, or for whom consent may be provided by guardian, unless informed consent provided by a guardian or a legally authorized representative is not consistent with applicable local or ethical concerns, procedures, directives and/or guidelines.

- Subject must have at least one of the following clinical presentations at Screening:

1. Oral temperature = 38.0 °C (=100.4 °F), =38.6°C (=101.4 °F) tympanic or rectal OR

2. Oxygen saturation <92%, OR

3. Two out of the following three vital signs:

Respiration rate >24/minute, Heart rate >100/minute, Systolic BP <90 mmHg

- Presence of at least one respiratory symptom (cough, sore throat, or nasal congestion) of any severity (mild, moderate, or severe).

- Presence of at least one constitutional symptom (headache, myalgia, feverishness, or fatigue) of any severity (mild, moderate, or severe).

- Onset of illness no more than 72 hours before presentation. Note: Time of onset of illness is defined as the earlier of either (1) the time when the temperature was first measured as elevated, OR (2) the time when the subject experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom.

- Either:

Severity of illness that, in the Investigator's judgment, justifies hospitalization of the subject for supportive care.

OR

Presence of one or more of the following factors:

Age =60 years. Presence of chronic obstructive pulmonary disease (COPD) or other chronic lung disease requiring daily pharmacotherapy.

Current history of congestive heart failure or angina. Presence of diabetes mellitus, clinically stable or unstable. Transcutaneous oxygen saturation <94% without supplemental oxygen for at least 5 minutes, or a medically significant decrease in oxygen saturation from an established baseline value (an investigative site at altitude >2000 ft above sea level will utilize different criteria for oxygen saturation).

History of chronic renal impairment not requiring peritoneal dialysis. Serum creatinine > 2.0 mg/dL or > 177 µmol/L.

- Diagnosis of Influenza by satisfying one of the following:

1. Clinical Influenza with Positive Diagnostic Test. Subjects who have a positive rapid antigen test (RAT) for influenza A and/or influenza B (using a Sponsor-approved test kit), or positive test (using other methodology) for influenza A and/or B virus antigen or RNA performed in a clinical laboratory at the screening/enrollment evaluation are eligible for enrollment.

OR

2. Clinical Influenza with Negative Rapid Antigen Test (RAT). Subjects with a negative RAT test may be enrolled once the site has been approved by the Sponsor to enroll such subjects, based on documentation of an outbreak of influenza in the community. An influenza outbreak may be documented in the catchment area of the hospital via one of the following methods: 1) local confirmation of influenza A or B infection in the current influenza season by a) the institution's local laboratory, or b) the local public health system, or c) the national public health system, or d) a laboratory of a recognized multinational influenza surveillance scheme such as the European Influenza Surveillance Network (EISN); 2) prior enrollment of a RAT positive subject into this study at the same institution in the current influenza season.

Exclusion Criteria:

- Subjects who have been hospitalized for greater than 24 hours (not including time spent in the Emergency Department).

- Treatment with any dose(s) of rimantadine, amantadine, ribavirin, zanamivir, or oseltamivir in the previous 7 days.

- Blood platelet count of < 20 x 109/L at the time of the screening evaluation.

- Serum bilirubin > 6 mg/dL or > 105 µmol/L at time of screening evaluation.

- Serum ALT or AST > 5 times the upper limit of normal at time of screening evaluation.

- Congestive heart failure of NYHA Class III or Class IV functional status.

- Serum creatinine > 5.0 mg/dL or > 500 µmol/L at time of screening evaluation.

- Subjects who require peritoneal dialysis.

- Altered neurologic status as defined by a Glasgow Coma Score of = 9, unless medically induced.

- Females who are pregnant (positive urine or serum pregnancy test at screening evaluation) or breastfeeding.

- Actively undergoing systemic chemotherapy or radiotherapy treatment for a malignancy. Subjects who have completed treatment 30 days prior to enrollment are not excluded. Hormone treatment for cancer is also not excluded.

- Prior hematopoietic stem cell transplantation or solid organ transplant during the previous 4 months.

- HIV infection with a known CD4 count < 200 cells/mm3 unless on a stable highly active antiretroviral therapy (HAART) for at least 6 months.

- Presence of a pre-existing chronic infection that is undergoing or requiring medical therapy (eg, tuberculosis). Subjects with chronic osteomyelitis or Hepatitis B or C not requiring treatment are not excluded.

- Presence of any pre-existing illness that, in the opinion of the investigator, would place the subject at an unreasonably increased risk through participation in this study.

- Previous treatment with intravenous or intramuscular peramivir.

- Participation as a subject in any study of an experimental treatment for any condition within the 30 days prior to the time of the screening evaluation.

- Subjects diagnosed with Cystic Fibrosis.

- Subjects with confirmed clinical evidence of acute non-influenzal infection at the time of screening evaluation.

- Subjects who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Intervention

Drug:
Peramivir+SOC
Adults (= 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care. Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
Placebo+SOC
Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.

Locations

Country Name City State
Argentina Hospital del Torax Dr. Antonio A. Cetrangolo Buenos Aires
Brazil Hospital de Clinicas de Porto Alegre Porto Alegre RS
Bulgaria DDPPDI - Ruse Ruse
Bulgaria Fifth MHAT-Sofia, AD Sofia
Bulgaria MHAT - Tokuda Hospital Sofia, AD Sofia
Bulgaria Military Medical Academy - MHAT Sofia
Bulgaria MHAT - Tokuda Hospital Sofia, AD Stara Zagora
Bulgaria MHAT 'Dr. St. Cherkezov', AD Veliko Tarnovo
Canada St. Joseph's Healthcare Hamilton Hamilton Ontario
Chile Hospital Clinico Regional Dr. Guillermo Grant Benavente Concepcion
Chile Hosp. de Urgencia Asistencia Publica Dr. Alejandro del Rio Santiago
Czech Republic Fakultni nemocnice Brno Brno
Czech Republic Krajska zdravotni, a.s. - Masarykova nemocnice v Ustinad La Usti nad Labem
Germany Universitaetsklinikum Regensburg Regensburg
Hungary Fejer Megyei Szent Gyorgy Korhaz Szekesfehervar
Hungary Principal SMO Dr. Bugyi Istvan Korhaz Szentes Szentes
India Apollo First Med Hospitals Chennai Tamil Nadu
India Life Line Multispecialty Hospital Chennai Tamil Nadu
India Fortis Escort Hospital Jaipur Rajasthan
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States University of North Carolina at Chapel Hill AIDS Clinical Trials Unit Chapel Hill North Carolina
United States University of Virginia Health System Charlottesville Virginia
United States Remington-Davis, Inc. Columbus Ohio
United States DeKalb Medical Center Decatur Georgia
United States Wayne State University - Hutzel Hospital Detroit Michigan
United States Wayne State University, Department of Emergency Medicine Detroit Michigan
United States Kentucky Lung Clinic Hazard Kentucky
United States Regional Infection Diseases Infusion Center Inc. Lima Ohio
United States Medical Arts Associates, Ltd. Moline Illinois
United States Pulmonary Consultants PC Physicians Medical Group, Inc. Orange California
United States Carilion Infectious Disease Roanoke Virginia
United States William Beaumont Hospital Royal Oak Michigan
United States UC Davis Medical Center Sacramento California
United States VA Medical Center - Salem Salem Virginia
United States Sharp Chula Vista Medical Center San Diego California
United States Washington University School of Medicine St. Louis Missouri
United States ID Clinical Research, LTD Toledo Ohio
United States Medical College Of Ohio Toledo Ohio
United States William Beaumont Hospital Troy Michigan
United States Washington Hospital Center CAR Washington District of Columbia
United States Drogue Medical, LLC Wheat Ridge Colorado
United States Florida Hospital Winter Park Florida

Sponsors (2)

Lead Sponsor Collaborator
BioCryst Pharmaceuticals Department of Health and Human Services

Countries where clinical trial is conducted

United States,  Argentina,  Belgium,  Bosnia and Herzegovina,  Brazil,  Bulgaria,  Canada,  Chile,  Czech Republic,  Germany,  Hungary,  India,  Israel,  Latvia,  Lebanon,  Peru,  Poland,  Russian Federation,  Serbia,  Slovakia,  South Africa,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Time to Hospital Discharge Time to hospital discharge, defined as the number of days from initiation of study treatment until the subject was discharged from the hospital, was summarized by treatment group using the method of Kaplan-Meier. Subjects who were not discharged from the hospital were censored at their last study visit. 10 days No
Other Incidence of Influenza-Related Complications Influenza-related complications were defined as the occurrence of sinusitis, otitis, bronchitis, and pneumonia as reported on the influenza-related complications CRF. 10 days No
Other Number of Subjects Requiring More Than 5 Days of Study Drug Subjects who had not met the protocol-defined criteria of clinical resolution on Day 5 or who had detectable virus by RT-PCR from a sample collected on Study Day 4 after dosing continued their assigned treatment for a further 5 days. 10 days No
Other Survival at 14 and 28 Days After Initiation of Study Drug (Kaplan-Meier Estimate) Survival was calculated as the number of days from initiation of study drug until death or last contact. Estimates and 95% confidence intervals were calculated using the method of Kaplan-Meier and presented by treatment group. 28 days No
Other Initial Viral Sensitivity to Peramivir, Oseltamivir, and Zanamivir; IC50 (nM) Initial viral sensitivity to peramivir, oseltamivir, and zanamivir was assessed over time during the study, and was presented by influenza virus subtype. Initial assessment of susceptibility may have occurred at a post-baseline visit. Initial (baseline or post-baseline) and up to 10 days No
Other Change in Viral Sensitivity to Peramivir, Oseltamivir, and Zanamivir; Fold Change From Initial Viral sensitivity to peramivir, oseltamivir, and zanamivir was assessed over time during the study, and was presented as fold change from initial sensitivity by influenza virus subtype. Initial assessment of susceptibility may have occurred at a post-baseline visit. Initial (baseline or post-baseline) and up to 10 days No
Primary Time to Clinical Resolution (Kaplan-Meier Estimate) Time to clinical resolution was defined as the time in hours from initiation of study treatment until normalization of at least 4 of the 5 signs within the respective normalization criteria, maintained for at least 24-hours. Time to clinical resolution was summarized by treatment group using the method of Kaplan-Meier. For subjects who did not experience clinical resolution, values were censored at the date of their last non-missing assessment of clinical resolution during the study (whether this assessment occurred as an inpatient or as an outpatient). 10 days No
Secondary Change (Reduction) in Influenza Virus Titer The reduction in viral shedding was assessed as the change from baseline in log10 tissue culture infective dose50 (TCID50/mL) and RT-PCR and was summarized for each treatment group and study visit. Baseline and 24, 48, 108 hours No
Secondary Time to Alleviation of Clinical Symptoms of Influenza Time to alleviation of clinical symptoms of influenza was measured as the time from the first dose of study drug through the time period in which all 7 symptoms of influenza (cough, sore throat, nasal congestion, myalgia [aches and pains], headache, feverishness, and fatigue) were absent or rated as no greater than mild for at least 24 hours. Time to alleviation of symptoms was estimated using the method of Kaplan-Meier. Subjects who did not have resolution of any individual clinical sign were censored at the time of their last non-missing assessment of that sign. 10 days No
Secondary Time to Resolution of Fever (Kaplan-Meier Estimate) Time to resolution of fever was measured as the time from initiation of study treatment until resolution of fever, maintained for at least 24 hours; temperature measurements taken less than 4 hours after antipyretic use were treated as missing values. 10 days No
Secondary Time to Resumption of Usual Activities Time to resumption of usual activities was determined from the visual analog scale (scale ranged from 0 to 10 where 0 indicated subject was unable to perform usual activities at all and 10 indicated subject was able to perform all usual activities fully). Time to resumption of usual activities was summarized by treatment group using the method of Kaplan-Meier. 10 days No
Secondary Number of Subjects With ICU Admission The number of subjects requiring ICU admission post-randomization was summarized by treatment group. 10 days No
Secondary Duration of All ICU Admissions (Kaplan-Meier Estimate) Duration of postbaseline ICU admission was defined as the total number of days in the ICU for those subjects who had a post-baseline admission to the ICU. Only days starting after the initial postbaseline admission were included. If a subject's stay in the ICU was ongoing, the duration was censored at the last study visit. Subjects who did not have a postbaseline admission had a duration of 0. 10 days No
See also
  Status Clinical Trial Phase
Withdrawn NCT03472872 - A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache Phase 4
Withdrawn NCT05410366 - Safe Harbors in Emergency Medicine, Specific Aim 3
Withdrawn NCT02866084 - Neuromodulation Treatment of Vestibular Migraines N/A
Active, not recruiting NCT03537573 - Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care N/A
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Not yet recruiting NCT04352218 - Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache Phase 2
Completed NCT02734992 - Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers N/A
Completed NCT01327118 - Prostaglandin F2alpha in a Human Headache Model N/A
Completed NCT01153789 - Study of Oculomotor Dysfunction Leading to Children Vertigo N/A
Not yet recruiting NCT00969995 - Identification of Inflammatory Markers in Migraine Patients N/A
Not yet recruiting NCT00752921 - Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache Phase 4
Terminated NCT00291395 - PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers Phase 1
Completed NCT00212810 - Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache. Phase 4
Completed NCT00263094 - An End to the Yom Kippur (and Ramadan) Headache N/A
Completed NCT00135122 - Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache Phase 3
Completed NCT02475005 - An Intervention to Improve Adolescent Headache Self-management N/A
Completed NCT03163901 - The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury N/A
Completed NCT01664585 - Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life N/A
Completed NCT04632420 - Evaluation of Headache and Childbirth in a Chronic Pain Population
Recruiting NCT05033613 - Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease